fulzerasib
AXP000031.1 · Targeted small molecule
- Platform
- small molecule
- Targets
- KRAS
- Originator
- GenFleet Therapeutics
- Sponsor
- Innovent Biologics (Greater China); GenFleet Therapeutics (ex-China)
Names
| Name | Type | Source |
|---|---|---|
| fulzerasib | preferred name, INN | curator, ncit |
| Dupert | brand | press |
| GFH925 | code | ncit |
| IBI351 | code | ncit |
Cross-references
- NCI Thesaurus
- C199055
- FDA UNII
- 6D5B7F245W
Approvals
No regulatory approval recorded.
Clinical trials (14)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07601048 | A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment | Not yet recruiting | Phase 3 | 2026-06 | 2028-05 | 450 | KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment |
| NCT07581912 | Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases | Recruiting | Phase 2 | 2026-04-30 | 2028-12 | 40 | Cetuximab N01; Colorectal Cancer; Fulzerasib; KRAS G12C Mutant Advanced Solid Tumors |
| NCT07463677 | Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Not yet recruiting | Phase 2 | 2026-03-15 | 2028-05-31 | 55 | Lung Cancer (NSCLC) |
| NCT07492342 | Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC | Recruiting | Phase 2 | 2026-01-29 | 2027-03-31 | 30 | KRAS G12C Mutation; Neoadjuvant Therapy; Resectable NSCLC; Stage IB-IIIA NSCLC |
| NCT07198841 | IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation | Recruiting | Phase 2 | 2025-11-03 | 2027-09 | 48 | Lung Cancer (Non-Small Cell) |
| NCT06959589 | The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer | Enrolling by invitation | Phase 2 | 2025-05-22 | 2027-05-31 | 50 | Colorectal Cancer Metastatic; KRAS G12C Mutation |
| NCT06936644 | A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation | Not yet recruiting | Phase 2 | 2025-04-30 | 2027-04-30 | 39 | KRAS G12C Lung Cancer |
| NCT05756153 | A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation | Completed | Phase 1/2 | 2023-04-25 | 2025-04-30 | 47 | Advance Non-small Cell Lung Cancer |
| NCT05699993 | A Study of IBI351 in Healthy Subjects | Completed | Phase 1 | 2023-03-10 | 2023-10-16 | 24 | Healthy Subjects |
| NCT05626179 | A Study of [14C]IBI351 in Healthy Subjects | Completed | Phase 1 | 2023-02-18 | 2023-03-30 | 6 | Healthy Subjects |
| NCT05688124 | A Study of IBI351 in Healthy Subjects | Completed | Phase 1 | 2023-02-16 | 2023-10-16 | 24 | Healthy Subjects |
| NCT05504278 | Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation | Recruiting | Phase 1 | 2022-09-20 | 2025-05-31 | 144 | Advanced Non-Small Cell Lung Cancer |
| NCT05497336 | A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer | Terminated | Phase 1 | 2022-08-18 | 2025-01-24 | 8 | Colorectal Cancer |
| NCT05005234 | A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations | Completed | Phase 1/2 | 2021-09-13 | 2023-02-20 | 334 | KRAS G12C |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT07198620 | A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China | Not yet recruiting | 2025-10-01 | 2026-06-01 | 600 | Lung Cancer (NSCLC) | name in title: IBI351 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41926959 | Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. | The Lancet. Oncology | 2026 | cited by trial NCT05756153 |
| PMID 40715048 | Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies. | Signal transduction and targeted therapy | 2025 | cited by trial NCT05005234 |
| PMID 39127176 | Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024 | cited by trial NCT05005234 |
| PMID 39357276 | Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study. | European journal of cancer (Oxford, England : 1990) | 2024 | name in title: IBI351 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41786688 | Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells. | Cell death discovery | 2026 | name in title: fulzerasib |
| PMID 41998662 | MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis. | Respiratory research | 2026 | name in abstract: fulzerasib |
| PMID 42448637 | Development and Validation of a Sensitive UHPLC-MS/MS Analytical Method for Fulzerasib in Rat Plasma and its Application to Pharmacokinetics Studies. | Biomedical chromatography : BMC | 2026 | name in title: fulzerasib |
| PMID 42622884 | KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms. | Medical oncology (Northwood, London, England) | 2026 | name in abstract: IBI351 |
| PMID 42990959 | MRAS, SHOC2, PP1C and YAP1 mRNA level variations at 72 hours of targeted therapy in KRAS G12C-mutant non-small cell lung cancer cell lines. | Annals of translational medicine | 2026 | name in abstract: fulzerasib |
| PMID 43001251 | From "undruggable" to tractable: Therapeutic advances targeting Kristen rat sarcoma viral homolog glycine to cysteine mutation at codon 12 (KRAS G12C)-mutant cancers and emerging resistance mechanisms. | Cancer pathogenesis and therapy | 2026 | name in abstract: fulzerasib |
| PMID 39794111 | Revolutionizing NSCLC Treatment: Unleashing the Potential of IBI351 and Its Critical Care Impact. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2025 | name in title: IBI351 |
| PMID 39794112 | Letter Regarding "Revolutionizing NSCLC Treatment: Unleashing the Potential of IBI351 and Its Critical Care Impact". | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2025 | name in title: IBI351 |
| PMID 39820841 | Correction: Fulzerasib: First Approval. | Drugs | 2025 | name in title: fulzerasib |
| PMID 40381703 | An overview of PROTACs targeting KRAS and SOS1 as antitumor agents. | Bioorganic & medicinal chemistry letters | 2025 | name in abstract: fulzerasib |
| PMID 40701936 | Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors. | Journal of medicinal chemistry | 2025 | name in title: fulzerasib |
| PMID 40799453 | Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancer. | Translational lung cancer research | 2025 | name in abstract: IBI351 |
| PMID 41158041 | [Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant Non-small Cell Lung Cancer]. | Zhongguo fei ai za zhi = Chinese journal of lung cancer | 2025 | name in abstract: fulzerasib |
| PMID 39433508 | Study of the mass balance, biotransformation, and safety of [ 14C]IBI351 in healthy Chinese subjects. | Journal of biomedical research | 2024 | name in title: IBI351 |
| PMID 39587006 | Fulzerasib: First Approval. | Drugs | 2024 | name in title: fulzerasib |
| PMID 25945295 | Arthroplasty for fifth carpometacarpal joint arthritis. | Journal of wrist surgery | 2015 | name in abstract: Dupert |
Notes
KRAS G12C. GenFleet code GFH925; Innovent code IBI351 after Sept 2021 China licence. Approved China Aug 2024 as Dupert. Wikidata QID not confirmed.
How to cite
fulzerasib (AXP000031.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000031.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.